In general news, Kate Middleton and Prince William gave birth to the third-in-line for the throne. In the U.S., Anthony Weiner, mayoral hopeful in New York City, made news again as his wife, Hillary Clinton top aid, became the focus. Also, SAC Capital was finally criminally indicted, one week after the SEC filed civil charges.
In healthcare business news, earning season continued with Big Pharma, biotech, and the hospitals reporting. In M&A, Amgen prepares to acquire ONXX, lining up funding. Lonza cancelled a generic drug venture with Teva. Kyprolis, not Nexavar, is the main prize. Medtronic and Amgen partnered to sell osteoporosis drug Prolia via spine surgery sales reps, perhaps to offset losses expected to come from lower InFuse sales, in the wake of the bad Yale analysis. Lastly, the Chinese arrests of Glaxo (GSK) employees continued.
On the data front, Roche’s replacement for Rituxan, GA101, or obinutuzumab, posted good data in the CLL setting, as Rituxan patents are set to expire. Isis (ISIS) drug ISIS-APOCIIIRx seemed to be effective in patients with elevated cholesterol. Biogen Idec’s (BIIB) new Tecfidera was related to a patient death from dehydration. Lastly, the pharmaceutical industry pledged to make more clinical trial data open and transparent.
From the FDA, Vertex (VRTX) shares fell after the FDA put a hold on trials of HCV drug VX-135. Sarepta (SRPT) announced plans to file for approval next year on eteplirsen to treat Duchenne muscular dystrophy. Elsewhere, the food division of the FDA announced pans to require imported food to be inspected more.